The Evolving Systemic Treatment for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which remains a global health challenge, with an estimated incidence of more than 1 million cases by 2025. The current major progress has improved the management of patients with advanced disease. Systemic treatments with mu...
Saved in:
| Main Authors: | Sara De Dosso, Marco Cefali, Maria Celeste Palmarocchi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.10.057 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy
by: Maria Celeste Palmarocchi, et al.
Published: (2021-03-01) -
Precision Oncology in Gastro-Esophageal Adenocarcinoma
by: Marco Cefalì, et al.
Published: (2020-10-01) -
Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report
by: Maria Celeste Palmarocchi, et al.
Published: (2022-03-01) -
The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma
by: Xinyu Guo, et al.
Published: (2025-04-01) -
Immunotherapy and Tumor Heterogeneity in Advanced Goblet Cell Adenocarcinoma of the Appendix: A Case Report
by: Jana Pankovics, et al.
Published: (2024-12-01)